Catalyst
Slingshot members are tracking this event:
BI187004 did not achieve the predefined primary efficacy endpoint criteria. As a result, Boehringer Ingelheim has informed Vitae of its intention to terminate the program and its corresponding license agreement.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VTAE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 17, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bi187004, Vtp-34072, Type 2 Diabetes
